Efficacy and Safety Study of SCYX-7158 in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study

Trial Profile

Efficacy and Safety Study of SCYX-7158 in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Acoziborole (Primary)
  • Indications African trypanosomiasis
  • Focus Therapeutic Use
  • Acronyms OXA002
  • Most Recent Events

    • 16 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 10 Sep 2015 New trial record
    • 08 Sep 2015 According to a Drugs for Neglected Diseases Initiative Foundation media release, recruitment is expected to be initiated in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top